Overview
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is performed to confirm the optimal dose for THR (total hip replacement).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
SanofiTreatments:
Enoxaparin
Enoxaparin sodium
Criteria
Inclusion Criteria:- Patients undergoing elective primary THR (total hip replacement) surgery
Exclusion Criteria:
- Patient with risk of clinical significant bleeding